Cadrenal Therapeutics, Inc. (CVKD)Healthcare | Biotechnology | Ponte Vedra, United States | NasdaqCM
2.42 USD
-0.47
(-16.263%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.45 +0.03 (1.240%) ⇧ (July 13, 2026, 7:57 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:25 a.m. EDT
The immediate outlook is severely clouded by a negative statistical forecast predicting a nearly 10% drop over the next 45 days, compounded by a recent price trend that has fallen significantly below both the 50-day and 200-day moving averages. While the company recently reported narrowing losses and secured capital through a private placement, the departure of the Chief Medical Officer adds executive instability to an already precarious operational picture. Fundamentally, the business remains in a deep burn phase with negative free cash flow and no earnings, trading at a forward P/E that indicates no profitability is expected soon. The lack of a dividend is unsurprising given the cash burn, but the combination of dilution, leadership changes, and weak technical momentum suggests the near-term path is down. Long-term, while the pipeline shows some progress, the multi-year trajectory has been brutal, wiping out half the shareholder value in just two years, and the current valuation does not yet reflect a sustainable turnaround. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.131543 |
| AutoARIMA | 0.243995 |
| AutoETS | 0.244407 |
| MSTL | 0.245139 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 3.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.234 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 7,449,358 |
| Forward P/E | -0.62 |
| Beta | 1.75 |
| Website | https://www.cadrenal.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7688 |
| Address1 | 822 A1A North |
| Address2 | Suite 306 |
| All Time High | 101.25 |
| All Time Low | 2.55 |
| Ask | 2.98 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 96,080 |
| Average Daily Volume3 Month | 74,280 |
| Average Volume | 74,280 |
| Average Volume10Days | 96,080 |
| Beta | 1.752 |
| Bid | 2.39 |
| Bid Size | 1 |
| Book Value | 0.717 |
| City | Ponte Vedra |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.42 |
| Current Ratio | 2.681 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.17 |
| Day Low | 2.34 |
| Display Name | Cadrenal Therapeutics |
| Earnings Timestamp End | 1,755,777,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -12,045,667 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.385 |
| Enterprise Value | 4,633,020 |
| Eps Current Year | -7.74 |
| Eps Forward | -3.91 |
| Eps Trailing Twelve Months | -5.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.40636 |
| Fifty Day Average Change | -1.9863601 |
| Fifty Day Average Change Percent | -0.45079386 |
| Fifty Two Week Change Percent | -76.880005 |
| Fifty Two Week High | 14.64 |
| Fifty Two Week High Change | -12.22 |
| Fifty Two Week High Change Percent | -0.83469945 |
| Fifty Two Week Low | 2.34 |
| Fifty Two Week Low Change | 0.08000016 |
| Fifty Two Week Low Change Percent | 0.034188103 |
| Fifty Two Week Range | 2.34 - 14.64 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,225,000,000 |
| Float Shares | 2,442,714 |
| Forward Eps | -3.91 |
| Forward P E | -0.6189258 |
| Free Cashflow | -6,599,821 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14836 |
| Held Percent Institutions | 0.03304 |
| Implied Shares Outstanding | 3,078,247 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. |
| Long Name | Cadrenal Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 7,449,358 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1793167154 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -11,888,522 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,896,133 |
| Number Of Analyst Opinions | 3 |
| Open | 3.12 |
| Operating Cashflow | -10,955,128 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 904 300 0701 |
| Post Market Change | 0.029999971 |
| Post Market Change Percent | 1.2396683 |
| Post Market Price | 2.45 |
| Post Market Time | 1,783,987,033 |
| Previous Close | 2.89 |
| Price Eps Current Year | -0.31266153 |
| Price Hint | 4 |
| Price To Book | 3.3751745 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.172 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.47 |
| Regular Market Change Percent | -16.263 |
| Regular Market Day High | 3.17 |
| Regular Market Day Low | 2.34 |
| Regular Market Day Range | 2.34 - 3.17 |
| Regular Market Open | 3.12 |
| Regular Market Previous Close | 2.89 |
| Regular Market Price | 2.42 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 269,251 |
| Return On Assets | -1.39242 |
| Return On Equity | -3.00587 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,078,247 |
| Shares Percent Shares Out | 0.026600001 |
| Shares Short | 82,016 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 68,650 |
| Short Name | Cadrenal Therapeutics, Inc. |
| Short Percent Of Float | 0.0313 |
| Short Ratio | 1.1 |
| Source Interval | 15 |
| State | FL |
| Symbol | CVKD |
| Target High Price | 45.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 27.66667 |
| Target Median Price | 25.0 |
| Total Cash | 2,308,137 |
| Total Cash Per Share | 0.805 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.753505 |
| Two Hundred Day Average Change | -5.333505 |
| Two Hundred Day Average Change Percent | -0.6878831 |
| Type Disp | Equity |
| Volume | 269,251 |
| Website | https://www.cadrenal.com |
| Zip | 32,082 |